285 related articles for article (PubMed ID: 23395171)
21. Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.
Mun SH; Won HY; Hernandez P; Aguila HL; Lee SK
J Bone Miner Res; 2013 Apr; 28(4):948-59. PubMed ID: 23044992
[TBL] [Abstract][Full Text] [Related]
22. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
23. Regulation of RANKL-induced osteoclastogenesis by RING finger protein RNF114.
Lin B; Ke Q; Leaman DW; Goel V; Agarwal A
J Orthop Res; 2018 Jan; 36(1):159-166. PubMed ID: 28708287
[TBL] [Abstract][Full Text] [Related]
24. Asperpyrone A attenuates RANKL-induced osteoclast formation through inhibiting NFATc1, Ca
Chen X; Wang C; Qiu H; Yuan Y; Chen K; Cao Z; Xiang Tan R; Tickner J; Xu J; Zou J
J Cell Mol Med; 2019 Dec; 23(12):8269-8279. PubMed ID: 31612613
[TBL] [Abstract][Full Text] [Related]
25. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway.
Yoon SH; Ryu Jy; Lee Y; Lee ZH; Kim HH
J Bone Miner Res; 2011 Jun; 26(6):1217-29. PubMed ID: 21611964
[TBL] [Abstract][Full Text] [Related]
26. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production.
Yip KH; Zheng MH; Steer JH; Giardina TM; Han R; Lo SZ; Bakker AJ; Cassady AI; Joyce DA; Xu J
J Bone Miner Res; 2005 Aug; 20(8):1462-71. PubMed ID: 16007343
[TBL] [Abstract][Full Text] [Related]
27. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
28. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
29. RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation.
Yang S; Li YP
Genes Dev; 2007 Jul; 21(14):1803-16. PubMed ID: 17626792
[TBL] [Abstract][Full Text] [Related]
30. Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling.
Park-Min KH; Lee EY; Moskowitz NK; Lim E; Lee SK; Lorenzo JA; Huang C; Melnick AM; Purdue PE; Goldring SR; Ivashkiv LB
J Bone Miner Res; 2013 Jan; 28(1):135-49. PubMed ID: 22893614
[TBL] [Abstract][Full Text] [Related]
31. Cyclic Dinucleotides Inhibit Osteoclast Differentiation Through STING-Mediated Interferon-β Signaling.
Kwon Y; Park OJ; Kim J; Cho JH; Yun CH; Han SH
J Bone Miner Res; 2019 Jul; 34(7):1366-1375. PubMed ID: 30779854
[TBL] [Abstract][Full Text] [Related]
32. The tethering function of mitofusin2 controls osteoclast differentiation by modulating the Ca
Ballard A; Zeng R; Zarei A; Shao C; Cox L; Yan H; Franco A; Dorn GW; Faccio R; Veis DJ
J Biol Chem; 2020 May; 295(19):6629-6640. PubMed ID: 32165499
[TBL] [Abstract][Full Text] [Related]
33. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
[TBL] [Abstract][Full Text] [Related]
34. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
35. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
36. IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).
Chen Z; Su L; Xu Q; Katz J; Michalek SM; Fan M; Feng X; Zhang P
J Biol Chem; 2015 Dec; 290(50):30163-74. PubMed ID: 26483549
[TBL] [Abstract][Full Text] [Related]
37. Cinchonine inhibits osteoclast differentiation by regulating TAK1 and AKT, and promotes osteogenesis.
Jo YJ; Lee HI; Kim N; Hwang D; Lee J; Lee GR; Hong SE; Lee H; Kwon M; Kim NY; Kim HJ; Park JH; Kang YH; Kim HS; Lee SY; Jeong W
J Cell Physiol; 2021 Mar; 236(3):1854-1865. PubMed ID: 32700766
[TBL] [Abstract][Full Text] [Related]
38. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
Han B; Geng H; Liu L; Wu Z; Wang Y
Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
[TBL] [Abstract][Full Text] [Related]
39. CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.
Xue P; Hu X; Powers J; Nay N; Chang E; Kwon J; Wong SW; Han L; Wu TH; Lee DJ; Tseng H; Ko CC
Biochem Biophys Res Commun; 2019 Apr; 511(3):637-643. PubMed ID: 30826055
[TBL] [Abstract][Full Text] [Related]
40. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation.
Chen K; Yuan Y; Wang Z; Song D; Zhao J; Cao Z; Chen J; Guo Q; Chen L; Tickner J; Xu J
J Cell Physiol; 2019 May; 234(5):6477-6488. PubMed ID: 30341897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
